New 2012 ADA/EASD Hyperglycemia Management Guidelines

by Ann Valtez, MD




Question from Dr. Ann Valdez: What were the 2012 ADA/EASD guidelines, and are they still current?


Follow-up: What are DPP-4 inhibitors, and which medicines belong to this class?





Quick Answer


The 2012 ADA/EASD statement helped move type 2 diabetes care from a rigid medication algorithm toward individualized, patient-centered treatment. That principle remains important, but its medication sequence is outdated.


Current care follows the newer ADA/EASD consensus and the ADA Standards of Care—2026, with greater emphasis on heart disease, heart failure, kidney disease, weight, hypoglycemia, cost, access, and patient preferences—not HbA1c alone.




Answer by Dr. Albana Greca, MD, MMedSc



Dear Dr. Ann,



The 2012 ADA/EASD statement emphasized shared decision-making, individualized HbA1c targets, lifestyle support, metformin as the usual initial medicine when appropriate, and timely addition of other therapies.



It should now be treated as a historical document. It was followed by updates in 2015 and 2018 and a new ADA/EASD consensus in 2022. The ADA also updates its Standards every year.




2012 ADA EASD principles compared with current type 2 diabetes care

The patient-centered principle remains relevant, but treatment recommendations must follow current ADA and ADA/EASD guidance.




What the Current Approach Means



For many nonpregnant adults, an HbA1c below 7% remains a common goal, but it must be individualized. Tighter goals may be suitable when they can be reached safely; less stringent goals may be appropriate when severe hypoglycemia, frailty, limited life expectancy, advanced complications, or treatment burden outweigh expected benefit.



Healthy eating, physical activity, diabetes self-management education, sleep, smoking cessation, and weight management remain essential. They support medication rather than replacing it when medicine is needed.



Metformin remains effective and commonly used. However, clinicians no longer need to wait for metformin failure before using an SGLT2 inhibitor or GLP-1 receptor agonist when cardiovascular disease, heart failure, chronic kidney disease, or weight goals make those benefits important.



Insulin is not a last-resort failure. It may be needed early with severe or symptomatic hyperglycemia, catabolism, ketosis, or inadequate control. In many other adults, a GLP-1–based therapy is considered before insulin.



What Are DPP-4 Inhibitors?



DPP-4 inhibitors reduce the breakdown of the incretin hormones GLP-1 and GIP. When glucose is normal or elevated, these hormones increase insulin release and reduce glucagon, lowering fasting and after-meal glucose.



Examples include sitagliptin, linagliptin, saxagliptin, alogliptin, and vildagliptin, which is available in many countries but not approved in the United States.



They usually produce modest glucose lowering, are weight neutral, and have a low hypoglycemia risk when used without insulin or a sulfonylurea. Most require kidney-dose adjustment; linagliptin generally does not.



The old answer suggested broad immune-system harm. That wording was unsupported. Important warnings instead include pancreatitis, severe joint pain, and bullous pemphigoid. Heart-failure risk needs particular attention with saxagliptin and alogliptin, especially in people with heart failure or kidney impairment.



DPP-4 inhibitors are generally not combined with GLP-1 receptor agonists because the combination adds little benefit.




Important Safety Note


Do not start, stop, or replace metformin, insulin, a DPP-4 inhibitor, an SGLT2 inhibitor, a GLP-1 medicine, or another treatment based on an old guideline. Severe hyperglycemia with vomiting, ketones, deep breathing, confusion, dehydration, or marked weakness needs urgent assessment.





Doctor’s Note


The lasting contribution of the 2012 statement was its patient-centered philosophy. Today, two people with the same HbA1c may appropriately receive different treatment because their heart, kidneys, weight goals, hypoglycemia risk, costs, and preferences differ.





Educational only: This answer does not replace an individualized medical assessment or prescribing decision.




Related Questions




Related Resources




References



  1. ADA/EASD 2012 patient-centered statement.

  2. ADA/EASD 2022 consensus report.

  3. ADA Pharmacologic Approaches—2026.

  4. ADA Glycemic Goals—2026.

  5. FDA sitagliptin/metformin prescribing information—2026.



Last reviewed: July 2026.



Click here to post comments or follow up

Ask the Doctor now? Simply click here to return to Type 2 diabetes information.